Increase
Decrease
Normal
Current Size:
100%
Search
Search
Home
About us
News
Contact us
General overview
Governance
Vacancies
Our staff
Links
Video gallery
Customer charter
Data & statistics
Data we collect
Data fields we collect
Performance indicators
Cancer factsheets
Incidence statistics
Survival Statistics
Incidence rates mapped
Data request
Publications
Annual financial reports
Strategic plans
Cancer trends & projections
Statistical reports
Cancer atlases
Research publications
Research reports
Scientific papers
Presentations
All Ireland cancer statistics
Infographics
Research
Research projects
Research publications
Research reports
Scientific papers
Presentations
FAQs
All FAQs
FAQs about us
About our data & how we collect it
Using & interpreting our data
Cancer information
Troubleshooting
Home
About us
News
Contact us
General overview
Governance
Vacancies
Our staff
Links
Video gallery
Customer charter
Data & statistics
Data we collect
Data fields we collect
Performance indicators
Cancer factsheets
Incidence statistics
Survival Statistics
Incidence rates mapped
Data request
Publications
Annual financial reports
Strategic plans
Cancer trends & projections
Statistical reports
Cancer atlases
Research publications
Research reports
Scientific papers
Presentations
All Ireland cancer statistics
Infographics
Research
Research projects
Research publications
Research reports
Scientific papers
Presentations
FAQs
All FAQs
FAQs about us
About our data & how we collect it
Using & interpreting our data
Cancer information
Troubleshooting
Data & statistics
Performance indicators
8E: Treatment - chemotherapy
Data we collect
Data fields we collect
Performance indicators
Cancer factsheets
Incidence statistics
Survival Statistics
Incidence rates mapped
Data request
Request specific grouped data
8E: Treatment - chemotherapy
% of Cases treated with Chemotherapy
UKIACR average (population)
UKIACR average (country)
England
Scotland
Wales
Northern Ireland
Republic of Ireland
All invasive xnmsc
25.8%
23.7%
26.5%
26.2%
20.3%
25.7%
19.8%
All xnmsc 0-24
56.7%
48.3%
60.3%
60.6%
51.7%
55.1%
14.0%
All xnmsc 25-59
39.4%
37.0%
40.4%
43.2%
33.5%
40.9%
27.1%
All xnmsc 60-79
26.4%
23.7%
27.3%
25.8%
21.1%
24.5%
19.6%
All xnmsc 80+
7.8%
6.7%
8.2%
6.3%
4.7%
7.3%
6.9%
Haematology
51.5%
46.8%
52.9%
58.6%
34.3%
52.8%
35.5%
Head and Neck
28.9%
25.2%
30.4%
25.6%
28.8%
24.6%
16.6%
Lower GI
31.5%
28.5%
32.5%
30.0%
24.7%
28.5%
26.8%
Upper GI
38.8%
35.7%
40.4%
36.6%
30.5%
43.3%
28.0%
HPB
23.6%
21.3%
24.7%
19.9%
15.8%
26.5%
19.5%
Trachea, Bronchus & Lung
28.1%
24.9%
29.4%
23.4%
24.2%
24.0%
23.4%
Melanoma
1.1%
1.2%
1.1%
0.4%
2.2%
1.0%
1.5%
Breast
31.7%
31.0%
31.9%
33.3%
25.9%
33.4%
30.6%
Cervix
34.7%
35.1%
34.6%
43.0%
26.0%
49.4%
22.6%
Other Female Genitals
29.2%
28.6%
29.3%
33.9%
22.2%
32.4%
25.2%
Prostate
3.2%
3.1%
3.2%
5.6%
3.7%
2.6%
0.4%
Kidney
8.4%
8.0%
8.6%
4.0%
9.7%
8.0%
9.9%
Bladder
29.7%
25.2%
31.1%
28.7%
22.9%
28.2%
15.0%
Brain and CNS
27.1%
23.4%
28.4%
33.5%
11.5%
29.9%
13.5%
Thyroid & other endocrine glands
4.7%
4.6%
4.8%
4.7%
5.6%
4.6%
3.5%
CUP
11.8%
8.7%
12.9%
7.7%
5.3%
5.5%
12.0%
Other invasive cancer
28.8%
24.2%
30.6%
25.6%
21.1%
26.3%
17.3%
Breast in situ
1.3%
1.3%
1.4%
0.6%
0.0%
3.8%
0.9%
Cervix in situ
0.0%
0.0%
0.0%
0.0%
0.0%
0.2%
0.0%
Other tumours
11.1%
8.3%
12.7%
11.3%
5.3%
9.2%
3.2%
Non-Melanoma Skin Cancer
0.1%
0.4%
0.1%
0.6%
0.2%
0.9%
0.1%
Printer-friendly version